You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 123 No. 11, November 1987 TABLE OF CONTENTS
  Archives
  •  Online Features
  STUDIES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (12)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Evaluation of Oral Minoxidil in the Treatment of Alopecia Areata

Virginia C. Fiedler-Weiss, MD; Jean Rumsfield, PharmD; Cunera M. Buys, MS; Dennis P. West, MS; Andrea Wendrow

Arch Dermatol. 1987;123(11):1488-1490.


Abstract

• A dose-response effect has previously been demonstrated in topical minoxidil treatment of alopecia areata. Limitations in minoxidil solubility and percutaneous absorption have impaired the development of more effective topical therapy. Oral minoxidil (5 mg every 12 hours), a dose demonstrated to be relatively well tolerated if a 2-g sodium diet is strictly followed, was given to 65 patients with severe, treatment-resistant alopecia areata in an attempt to bypass the limitations of topical treatment and increase efficacy. Although hair regrowth progressed more rapidly and was more extensive with oral than topical 5% minoxidil, cosmetic response was seen only in 18% of the patients. Neither serum nor tissue levels of minoxidil correlated with response. These findings suggest that improved preparations of topical minoxidil, when used as a single therapeutic agent, are unlikely to be cosmetically effective in the majority of patients with severe alopecia areata.

(Arch Dermatol 1987;123:1488-1490)



Author Affiliations

From the Departments of Dermatology (Drs Fiedler-Weiss, Rumsfield, and Ms Buys) and Pharmacy Practice (Mr West and Ms Wendrow), the University of Illinois at Chicago.


Footnotes

Accepted for publication May 7, 1987.

Presented in part at the Annual Meeting of the American Academy of Dermatology, New Orleans, Dec 8, 1986.

Reprint requests to University of Illinois College of Medicine at Chicago, Department of Dermatology (M/C 624), PO Box 6998, Chicago, IL 60680 (Dr Fiedler-Weiss).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Alopecia Areata: A Review of Therapy, Efficacy, Safety, and Mechanism
Fiedler
Arch Dermatol 1992;128:1519-1529.
ABSTRACT  

Treatment-Resistant Alopecia Areata: Response to Combination Therapy With Minoxidil Plus Anthralin
Fiedler et al.
Arch Dermatol 1990;126:756-759.
ABSTRACT  

Evaluation of Anthralin in the Treatment of Alopecia Areata
Fiedler-Weiss and Buys
Arch Dermatol 1987;123:1491-1493.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1987 American Medical Association. All Rights Reserved.